Hub : Traits :

Depressed Affect (Nagel 2018)

690 significantly associated models · 109 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 1 7715776 9571422 2 1 3.3e-08 1.8e-08 1.0e+00 100 RP5-1115A15.1
2 1 86635245 88508392 2 2 1.7e-07 3.1e-06 2.4e-02 77 LMO4 SEP15
3 1 242590540 244112606 1 1 2.7e-07 1.6e-06 4.1e-01 97 CEP170
4 2 23453834 25141538 4 1 1.3e-11 5.4e-11 9.0e-03 84 UBXN2A
5 2 147993969 149475737 2 1 7.1e-08 9.5e-10 2.4e-03 76 ORC4L
6 2 202952678 204421284 1 1 2.3e-07 2.2e-06 6.0e-01 99 ICA1L
7 2 219863589 220358586 2 1 4.9e-08 3.7e-07 7.4e-02 88 GLB1L
8 3 16154636 17814553 1 1 8.2e-08 3.3e-10 1.5e-04 64 PLCL2
9 3 48335857 50800146 22 1 8.3e-15 4.2e-10 3.0e-01 97 GPX1
10 3 135806811 136715468 1 1 1.1e-09 2.6e-09 1.0e+00 100 STAG1
11 5 87104604 88677293 1 1 8.9e-08 1.9e-09 6.4e-03 79 LINC00461
12 5 119109286 120721018 1 1 7.4e-09 1.7e-08 1.0e+00 100 PRR16
13 7 1580921 2977732 1 1 6.9e-08 6.3e-08 3.5e-03 71 FTSJ2
14 7 11553163 12967449 1 1 1.2e-10 5.1e-11 1.0e+00 100 TMEM106B
15 8 21720054 22214508 1 1 2.8e-08 8.4e-06 6.8e-01 99 NUDT18
16 8 141421996 142253369 1 1 1.9e-07 6.6e-07 8.7e-01 100 PTK2
17 9 95502571 96898436 1 1 9.7e-08 3.9e-08 1.2e-05 37 RP11-165J3.6
18 9 119768572 121177842 1 1 5.9e-10 2.3e-09 1.8e-02 84 TLR4
19 11 12611333 14105497 1 1 6.6e-08 6.1e-07 8.0e-01 100 ARNTL
20 11 46010847 48559571 18 8 1.9e-15 6.0e-14 NaN NaN ARHGAP1 C1QTNF4 LRP4 MADD NUP160
21 11 112135760 113969669 5 2 9.1e-14 1.8e-13 1.0e+00 100 DRD2 RP11-159N11.4
22 12 109295508 110704487 2 1 4.3e-08 5.1e-09 3.9e-02 88 MMAB
23 13 66643767 68053176 1 1 2.3e-08 1.9e-06 1.1e-04 34 PCDH9
24 14 74531485 76089054 3 1 1.0e-09 2.1e-10 6.6e-02 92 DLST
25 15 77207277 78806023 1 1 3.1e-07 3.8e-10 2.3e-05 54 LINGO1
26 16 70624483 72022941 1 1 2.2e-07 2.3e-06 3.5e-01 96 CMTR2
27 16 88523815 89030118 1 1 1.5e-07 9.9e-07 2.5e-01 94 CTU2
28 17 42607368 45796313 20 1 1.1e-22 1.4e-21 9.3e-02 97 WNT3
29 17 78843139 79380547 1 1 1.4e-07 4.0e-07 1.0e+00 100 AATK
30 18 34614002 35378540 1 1 1.1e-07 3.5e-12 5.6e-06 57 CELF4
31 18 49172179 51753106 1 1 2.5e-08 3.9e-12 4.3e-06 56 DCC
32 18 52209411 54028036 1 1 1.9e-08 8.3e-17 8.1e-15 13 TCF4
33 19 32151452 33668090 2 1 2.1e-11 1.1e-10 1.0e+00 100 DPY19L3
34 20 43958786 45456440 2 2 9.4e-11 1.8e-11 1.0e+00 100 CD40 SLC12A5
35 22 38388203 39770597 1 1 6.6e-08 1.9e-07 1.0e+00 100 TOMM22

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Bipolar Disorder or Schizophrenia 2.14 4 0 0.0 0.81 1.9e-01 ARHGAP1 CEP170 DCC SLC12A5
Depression (Nagel 2018) 9.33 17 3 6.7 0.98 4.4e-12 AATK C1QTNF4 CMTR2 DCC DPY19L3 FTSJ2 MADD NUP160 PCDH9 RP11-159N11.4 RP11-165J3.6 RP5-1115A15.1 SLC12A5 STAG1 TMEM106B UBXN2A WNT3
Intelligence (Savage-Jansen 2018) 3.18 8 6 13.3 -0.07 8.5e-01 AATK C1QTNF4 GPX1 LINC00461 NUP160 PLCL2 STAG1 WNT3
Neuroticism (Nagel 2018) 15.53 39 30 66.7 0.99 8.2e-33 AATK ARHGAP1 ARNTL C1QTNF4 CD40 CELF4 CMTR2 CTU2 DCC DLST DPY19L3 DRD2 FTSJ2 GPX1 LINC00461 LINGO1 LMO4 LRP4 MADD MMAB NUDT18 NUP160 ORC4L PCDH9 PLCL2 PRR16 PTK2 RP11-159N11.4 RP11-165J3.6 RP5-1115A15.1 SEP15 SLC12A5 STAG1 TCF4 TLR4 TMEM106B TOMM22 UBXN2A WNT3
Schizophrenia (2018) 2.46 4 0 0.0 0.04 9.6e-01 ARHGAP1 DCC RP5-1115A15.1 STAG1
Schizophrenia vs Biploar Disorder 2.90 3 0 0.0 0.00 1.0e+00 ARHGAP1 ARNTL ICA1L
Worry (Nagel 2018) 8.52 16 10 22.2 0.99 1.6e-13 AATK ARNTL C1QTNF4 DLST DRD2 MADD MMAB NUP160 ORC4L PLCL2 RP11-159N11.4 RP11-165J3.6 SLC12A5 STAG1 TMEM106B WNT3
Alzheimer’s Disease (including proxy) 2.25 2 0 0.0 0.00 1.0e+00 C1QTNF4 MADD
Crohns Disease (2017) 1.58 3 1 2.2 0.00 1.0e+00 CD40 GPX1 SLC12A5
Irritable Bowel Disease (IBD) 1.55 3 1 2.2 0.00 1.0e+00 CD40 GPX1 SLC12A5
Ulcerative Colitis (UC) 1.21 1 1 2.2 0.00 1.0e+00 GPX1
Major Depression (MDD) 4.07 3 0 0.0 0.00 1.0e+00 GPX1 TCF4 TMEM106B
Reaction Time 3.06 2 1 2.2 -0.99 1.1e-02 ARHGAP1 LRP4
Verbal and Numeric Reasoning (VNR) 2.79 5 1 2.2 0.14 7.9e-01 C1QTNF4 GPX1 LINC00461 NUP160 STAG1
Breast Cancer 1.26 1 1 2.2 0.00 1.0e+00 WNT3
Ovarian Cancer 1.26 1 1 2.2 0.00 1.0e+00 WNT3
Prostate Cancer 1.76 1 0 0.0 0.00 1.0e+00 GPX1
Age at First Birth 2.02 1 1 2.2 0.00 1.0e+00 GPX1
Body Mass Index (BMI) (2010) 2.89 2 1 2.2 0.00 1.0e+00 C1QTNF4 MADD
Coronary Artery Disease (CAD) 1.87 1 0 0.0 0.00 1.0e+00 ICA1L
Mean Putamen Volume 1.38 1 0 0.0 0.00 1.0e+00 WNT3
Fasting Glucose 2.31 2 1 2.2 0.00 1.0e+00 LRP4 MADD
HDL Cholesterol 3.74 6 3 6.7 0.09 8.3e-01 ARHGAP1 C1QTNF4 DPY19L3 LRP4 MMAB NUP160
LDL Cholesterol 1.66 1 0 0.0 0.00 1.0e+00 CMTR2
Neuroticism (2016) 8.04 10 2 4.4 0.98 3.8e-08 C1QTNF4 CELF4 DRD2 GPX1 LINC00461 MADD PCDH9 TCF4 TLR4 WNT3
Primary Biliary Cirrhosis 1.68 2 0 0.0 0.00 1.0e+00 PLCL2 WNT3
Rheumatoid Arthritis 2.10 2 0 0.0 0.00 1.0e+00 CD40 SLC12A5
Schizophrenia (2014) 2.72 5 1 2.2 -0.12 8.5e-01 ARHGAP1 CEP170 DRD2 RP5-1115A15.1 STAG1
Triglycerides 1.64 1 0 0.0 0.00 1.0e+00 LRP4
Ulcerative Colitis 1.31 1 1 2.2 0.00 1.0e+00 GPX1
Blood Eosinophil Count 1.38 5 3 6.7 -0.94 1.6e-02 GPX1 ORC4L PLCL2 RP5-1115A15.1 WNT3
Blood Platelet Count 1.03 8 5 11.1 0.50 1.7e-01 C1QTNF4 DLST LINC00461 LRP4 MADD PTK2 TOMM22 WNT3
Blood Red Count 1.87 7 4 8.9 0.28 5.4e-01 ARNTL CMTR2 CTU2 DRD2 LINC00461 UBXN2A WNT3
Blood White Count 1.83 9 6 13.3 -0.05 9.0e-01 AATK C1QTNF4 GPX1 LINC00461 MADD NUP160 RP5-1115A15.1 UBXN2A WNT3
Heel T-Score 4.54 7 6 13.3 -0.69 4.0e-02 ARHGAP1 DLST LRP4 MADD RP5-1115A15.1 TOMM22 WNT3
BMI 3.73 10 6 13.3 -0.22 5.2e-01 ARNTL C1QTNF4 CEP170 FTSJ2 GPX1 LINC00461 MADD NUP160 RP11-159N11.4 TLR4
Height 1.73 19 17 37.8 -0.08 7.4e-01 AATK C1QTNF4 CMTR2 CTU2 DCC FTSJ2 GLB1L GPX1 LRP4 MADD NUP160 ORC4L RP11-165J3.6 RP5-1115A15.1 STAG1 TCF4 TMEM106B UBXN2A WNT3
Waist Hip Ratio (WHR) 1.45 6 3 6.7 -0.03 9.5e-01 GPX1 PTK2 RP11-159N11.4 STAG1 UBXN2A WNT3
Systolic Blood Pressure 3.17 10 6 13.3 0.49 1.0e-01 ARHGAP1 ARNTL C1QTNF4 CMTR2 GPX1 LRP4 MADD ORC4L PTK2 RP5-1115A15.1
Smoking Status 2.95 5 2 4.4 0.09 8.9e-01 AATK GPX1 NUP160 RP5-1115A15.1 WNT3
Allergy or Eczema 1.77 3 1 2.2 0.00 1.0e+00 PLCL2 RP5-1115A15.1 SLC12A5
Cardiovascular Disease 1.85 5 0 0.0 0.14 8.2e-01 ARNTL FTSJ2 NUDT18 RP11-159N11.4 RP5-1115A15.1
Hypothyroidism (self reported) 1.46 2 1 2.2 0.00 1.0e+00 C1QTNF4 RP5-1115A15.1
Respiratory disease 1.56 1 1 2.2 0.00 1.0e+00 RP5-1115A15.1
Type 2 Diabetes (T2D) (2018) 1.21 1 0 0.0 0.00 1.0e+00 C1QTNF4
Lung FEV1/FVC ratio 0.88 3 1 2.2 0.00 1.0e+00 DLST PRR16 RP5-1115A15.1
Lung FVC 2.31 5 3 6.7 -0.73 1.6e-01 DCC GPX1 TCF4 UBXN2A WNT3
Neuroticism 14.57 38 29 64.4 0.99 1.0e-31 AATK ARHGAP1 ARNTL C1QTNF4 CD40 CELF4 CEP170 CMTR2 CTU2 DLST DPY19L3 DRD2 FTSJ2 GPX1 ICA1L LINC00461 LINGO1 LRP4 MADD MMAB NUDT18 NUP160 ORC4L PCDH9 PLCL2 PRR16 PTK2 RP11-159N11.4 RP11-165J3.6 RP5-1115A15.1 SEP15 SLC12A5 STAG1 TCF4 TLR4 TMEM106B UBXN2A WNT3
Chronotype (morning person) 1.85 1 0 0.0 0.00 1.0e+00 C1QTNF4
Hair Pigment 0.26 4 2 4.4 -0.02 9.8e-01 CTU2 LRP4 RP5-1115A15.1 WNT3
Tanning 0.37 2 1 2.2 0.00 1.0e+00 C1QTNF4 CTU2
Hand grip strength (left) 2.88 5 4 8.9 -0.02 9.7e-01 C1QTNF4 LINGO1 MADD TCF4 WNT3
Number of treatments/medications taken 2.94 3 1 2.2 0.00 1.0e+00 DLST FTSJ2 GPX1
Sensitivity / hurt feelings 6.15 10 4 8.9 0.98 2.5e-07 CELF4 DRD2 MMAB ORC4L PLCL2 PTK2 RP11-159N11.4 RP11-165J3.6 STAG1 WNT3
Frequency of depressed mood in last 2 weeks 8.83 12 1 2.2 0.99 7.8e-10 AATK C1QTNF4 DRD2 MADD NUP160 PCDH9 RP11-165J3.6 RP5-1115A15.1 STAG1 TMEM106B UBXN2A WNT3
Hearing difficulty/problems: Yes 1.45 2 0 0.0 0.00 1.0e+00 MMAB PTK2
Relative age of first facial hair 2.17 1 1 2.2 0.00 1.0e+00 WNT3
Ever used hormone-replacement therapy (HRT) 2.31 1 0 0.0 0.00 1.0e+00 TOMM22
Systolic blood pressure, automated reading 2.29 5 3 6.7 0.34 5.7e-01 ARNTL GPX1 LRP4 MADD RP5-1115A15.1
Eye problems/disorders: Diabetes related eye disease 1.65 1 0 0.0 0.00 1.0e+00 C1QTNF4
Medication: Metformin 1.80 1 0 0.0 0.00 1.0e+00 C1QTNF4
Pack years adult smoking proportion 2.50 2 0 0.0 0.00 1.0e+00 CELF4 GPX1
Impedance of leg (right) 1.60 6 4 8.9 0.11 8.4e-01 C1QTNF4 GPX1 LINC00461 MADD STAG1 UBXN2A
Leg fat-free mass (left) 1.22 3 1 2.2 0.00 1.0e+00 ARHGAP1 C1QTNF4 LINC00461
Trunk fat percentage 3.93 13 6 13.3 -0.28 3.3e-01 ARNTL C1QTNF4 CEP170 DPY19L3 FTSJ2 GPX1 LINC00461 MADD NUDT18 NUP160 RP5-1115A15.1 UBXN2A WNT3
Hand grip strength (right) 2.20 6 3 6.7 -0.04 9.3e-01 C1QTNF4 LINGO1 LMO4 MADD TCF4 WNT3
Current tobacco smoking 3.26 5 1 2.2 0.71 1.1e-01 AATK C1QTNF4 CELF4 NUP160 RP5-1115A15.1
Fed-up feelings 11.49 26 12 26.7 0.99 1.1e-21 ARHGAP1 ARNTL CD40 CELF4 CMTR2 DCC DLST DPY19L3 DRD2 GPX1 LINC00461 LINGO1 LMO4 LRP4 MADD ORC4L PCDH9 PRR16 PTK2 RP11-159N11.4 SEP15 SLC12A5 STAG1 TLR4 UBXN2A WNT3
Frequency of unenthusiasm / disinterest in last 2 weeks 6.88 6 1 2.2 0.99 1.2e-04 DCC DRD2 PCDH9 RP11-159N11.4 STAG1 UBXN2A
Relative age voice broke 1.79 1 1 2.2 0.00 1.0e+00 WNT3
Taking other prescription medications 2.93 2 0 0.0 0.00 1.0e+00 DLST GPX1
Age when periods started (menarche) 2.94 5 4 8.9 1.00 3.6e-05 ARNTL C1QTNF4 GPX1 MADD NUP160
Heel bone mineral density (BMD) T-score, automated (left) 3.16 4 3 6.7 -0.80 5.9e-02 ARHGAP1 LRP4 RP5-1115A15.1 TOMM22
Qualifications: CSEs or equivalent 1.57 1 0 0.0 0.00 1.0e+00 WNT3
High blood pressure 2.37 5 2 4.4 0.46 3.6e-01 ARHGAP1 ARNTL LRP4 MADD RP5-1115A15.1
Hayfever, allergic rhinitis or eczema 1.65 1 1 2.2 0.00 1.0e+00 RP5-1115A15.1
Stomach or abdominal pain in last month 3.06 1 0 0.0 0.00 1.0e+00 STAG1
Medication: Atenolol 1.34 1 0 0.0 0.00 1.0e+00 ICA1L
Medication: Levothyroxine sodium 1.25 1 0 0.0 0.00 1.0e+00 RP5-1115A15.1
Sitting height 2.32 9 7 15.6 0.09 8.0e-01 AATK ARHGAP1 C1QTNF4 DCC LRP4 MADD NUP160 UBXN2A WNT3
Body mass index (BMI) 3.71 10 7 15.6 -0.16 6.4e-01 ARNTL C1QTNF4 DPY19L3 FTSJ2 GPX1 LINC00461 MADD NUP160 RP5-1115A15.1 STAG1
Impedance of leg (left) 1.58 8 3 6.7 -0.07 8.6e-01 C1QTNF4 FTSJ2 GPX1 LINC00461 MADD STAG1 UBXN2A WNT3
Leg predicted mass (left) 1.24 3 1 2.2 0.00 1.0e+00 ARHGAP1 C1QTNF4 LINC00461
Trunk fat mass 3.02 9 4 8.9 -0.33 3.5e-01 ARNTL C1QTNF4 CEP170 DPY19L3 GPX1 LINC00461 MADD RP5-1115A15.1 WNT3
Waist circumference 2.74 7 4 8.9 -0.14 7.4e-01 ARNTL C1QTNF4 DPY19L3 FTSJ2 LINC00461 MADD RP11-159N11.4
Past tobacco smoking 1.67 1 0 0.0 0.00 1.0e+00 WNT3
Alcohol usually taken with meals 2.21 1 1 2.2 0.00 1.0e+00 CELF4
Nervous feelings 5.37 7 3 6.7 0.99 2.1e-05 ARNTL C1QTNF4 DLST MADD ORC4L STAG1 WNT3
Frequency of tenseness / restlessness in last 2 weeks 6.99 11 3 6.7 0.99 3.6e-08 AATK C1QTNF4 DRD2 GPX1 MADD MMAB RP11-165J3.6 STAG1 TMEM106B UBXN2A WNT3
Hearing difficulty/problems with background noise 3.26 3 0 0.0 0.95 1.4e-02 ARHGAP1 LRP4 WNT3
Hair/balding pattern: Pattern 2 1.72 1 1 2.2 0.00 1.0e+00 WNT3
Forced vital capacity (FVC) 2.66 5 3 6.7 -0.07 9.0e-01 C1QTNF4 GPX1 LRP4 NUP160 WNT3
Heel bone mineral density (BMD) T-score, automated (right) 3.43 4 3 6.7 -0.76 8.1e-02 ARHGAP1 LRP4 RP5-1115A15.1 TOMM22
Ever unenthusiastic/disinterested for a whole week 2.60 1 0 0.0 0.00 1.0e+00 WNT3
Qualifications: None of the above 2.34 2 1 2.2 0.00 1.0e+00 CELF4 GPX1
Financial difficulties in last 2 years 2.76 1 0 0.0 0.00 1.0e+00 DRD2
Mouth/teeth dental problems 2.43 2 0 0.0 0.00 1.0e+00 CEP170 WNT3
Heart attack 1.66 1 0 0.0 0.00 1.0e+00 ICA1L
Allergy 1.53 1 1 2.2 0.00 1.0e+00 RP5-1115A15.1
Fluid intelligence score 2.88 5 3 6.7 0.32 5.4e-01 C1QTNF4 GPX1 MADD NUP160 STAG1
Neuroticism score 13.70 31 23 51.1 0.99 2.6e-27 AATK ARHGAP1 ARNTL C1QTNF4 CD40 CELF4 DLST DPY19L3 DRD2 FTSJ2 GPX1 LINC00461 LINGO1 LRP4 MADD MMAB NUP160 ORC4L PCDH9 PLCL2 PTK2 RP11-159N11.4 RP11-165J3.6 RP5-1115A15.1 SLC12A5 STAG1 TCF4 TLR4 TMEM106B UBXN2A WNT3
Weight 1.65 6 3 6.7 0.07 8.8e-01 C1QTNF4 CEP170 DPY19L3 GPX1 LINC00461 MADD
Impedance of arm (right) 1.46 5 3 6.7 -0.97 6.4e-03 GPX1 LINC00461 STAG1 TMEM106B WNT3
Arm fat percentage (right) 4.49 11 7 15.6 -0.25 4.3e-01 ARNTL C1QTNF4 DPY19L3 FTSJ2 GPX1 LINC00461 MADD NUDT18 NUP160 RP11-159N11.4 RP5-1115A15.1
Trunk fat-free mass 1.27 5 3 6.7 0.34 5.1e-01 ARHGAP1 C1QTNF4 LRP4 NUP160 UBXN2A
Hip circumference 2.12 8 4 8.9 0.10 7.9e-01 C1QTNF4 CEP170 DPY19L3 FTSJ2 GPX1 LINC00461 MADD TOMM22
Time employed in main current job 1.82 1 1 2.2 0.00 1.0e+00 WNT3
Alcohol intake versus 10 years previously 2.38 1 0 0.0 0.00 1.0e+00 FTSJ2
Father's age at death 1.78 1 0 0.0 0.00 1.0e+00 GPX1
Worrier / anxious feelings 5.67 10 4 8.9 0.98 4.4e-07 ARNTL DLST LINGO1 MMAB ORC4L RP11-165J3.6 STAG1 TCF4 TLR4 WNT3
Frequency of tiredness / lethargy in last 2 weeks 7.41 11 2 4.4 0.98 1.9e-08 AATK ARHGAP1 C1QTNF4 GPX1 MMAB ORC4L PTK2 RP11-165J3.6 RP5-1115A15.1 STAG1 UBXN2A
Hair/balding pattern: Pattern 3 2.31 1 1 2.2 0.00 1.0e+00 WNT3
Number of live births 1.59 1 0 0.0 0.00 1.0e+00 WNT3
Forced expiratory volume in 1-second (FEV1) 2.56 4 2 4.4 -0.93 2.4e-02 C1QTNF4 GPX1 UBXN2A WNT3
Pulse rate 1.50 2 1 2.2 0.00 1.0e+00 SEP15 TOMM22
Qualifications: A levels/AS levels or equivalent 2.36 2 1 2.2 0.00 1.0e+00 GPX1 LINC00461
Mouth/teeth dental problems: Dentures 1.65 2 0 0.0 0.00 1.0e+00 GPX1 STAG1
Asthma 1.50 1 1 2.2 0.00 1.0e+00 RP5-1115A15.1
Medication: Ibuprofen (e.g. Nurofen) 2.00 1 0 0.0 0.00 1.0e+00 UBXN2A
Depression (self-reported) 3.59 2 0 0.0 0.00 1.0e+00 RP5-1115A15.1 TMEM106B
Forced expiratory volume in 1-second (FEV1), Best measure 2.63 3 3 6.7 -0.97 2.5e-02 C1QTNF4 GPX1 WNT3
Impedance of arm (left) 1.50 3 3 6.7 0.00 1.0e+00 GPX1 STAG1 WNT3
Arm fat mass (right) 3.39 10 6 13.3 -0.22 5.1e-01 ARNTL C1QTNF4 DPY19L3 FTSJ2 GPX1 LINC00461 MADD NUP160 RP11-159N11.4 RP5-1115A15.1
Trunk predicted mass 1.25 5 3 6.7 0.34 5.1e-01 ARHGAP1 C1QTNF4 LRP4 NUP160 UBXN2A
Standing height 1.94 14 9 20.0 -0.07 8.1e-01 AATK C1QTNF4 FTSJ2 GLB1L GPX1 LRP4 MADD NUP160 RP11-165J3.6 RP5-1115A15.1 STAG1 TMEM106B UBXN2A WNT3
Tense / 'highly strung' 4.65 7 3 6.7 0.98 1.2e-04 AATK DRD2 ORC4L RP11-159N11.4 RP11-165J3.6 RP5-1115A15.1 TMEM106B
Seen doctor (GP) for nerves, anxiety, tension or depression 5.70 7 3 6.7 0.96 4.9e-04 CELF4 DRD2 FTSJ2 GPX1 SLC12A5 TCF4 TMEM106B
Hair/balding pattern: Pattern 4 3.55 2 1 2.2 0.00 1.0e+00 RP5-1115A15.1 WNT3
Peak expiratory flow (PEF) 1.75 2 1 2.2 0.00 1.0e+00 C1QTNF4 WNT3
Qualifications: O levels/GCSEs or equivalent 2.28 3 1 2.2 0.00 1.0e+00 GPX1 LINC00461 PLCL2
Medication: Paracetamol 3.36 3 3 6.7 0.00 1.0e+00 CEP170 GPX1 WNT3
Headache pain in last month 3.81 5 2 4.4 0.99 8.3e-04 CEP170 LMO4 NUDT18 TLR4 WNT3
Hypothyroidism/myxoedema (self-reported) 1.23 1 0 0.0 0.00 1.0e+00 RP5-1115A15.1
Birth weight 1.08 1 0 0.0 0.00 1.0e+00 C1QTNF4
Forced vital capacity (FVC), Best measure 2.99 5 3 6.7 -0.26 5.7e-01 C1QTNF4 GPX1 LRP4 NUP160 WNT3
Body fat percentage 4.07 13 6 13.3 -0.24 4.1e-01 ARNTL C1QTNF4 CEP170 DPY19L3 FTSJ2 GPX1 LINC00461 MADD NUDT18 NUP160 RP5-1115A15.1 UBXN2A WNT3
Leg fat percentage (right) 3.71 11 5 11.1 -0.12 7.1e-01 ARNTL C1QTNF4 DPY19L3 FTSJ2 GPX1 LINC00461 MADD NUDT18 NUP160 RP5-1115A15.1 UBXN2A
Arm fat-free mass (right) 1.06 3 0 0.0 0.00 1.0e+00 GPX1 LINC00461 NUP160
Comparative body size at age 10 3.20 5 4 8.9 -0.82 4.6e-02 C1QTNF4 LINC00461 MADD NUP160 RP11-165J3.6
Number of full brothers 1.80 1 0 0.0 0.00 1.0e+00 WNT3
Worry too long after embarrassment 5.06 7 3 6.7 0.92 3.7e-03 ARNTL DRD2 LINC00461 MMAB RP11-159N11.4 STAG1 WNT3
Seen a psychiatrist for nerves, anxiety, tension or depression 3.40 1 0 0.0 0.00 1.0e+00 TMEM106B
Wheeze or whistling in the chest in last year 2.24 3 0 0.0 0.00 1.0e+00 GPX1 RP11-165J3.6 RP5-1115A15.1
Age at first live birth 2.52 2 1 2.2 0.00 1.0e+00 CELF4 GPX1
Health satisfaction 3.22 3 0 0.0 0.00 1.0e+00 DRD2 GPX1 PCDH9
Qualifications: College or University degree 2.89 6 5 11.1 -0.42 4.1e-01 CELF4 CEP170 FTSJ2 GPX1 LINC00461 WNT3
Emphysema/chronic bronchitis 1.72 1 0 0.0 0.00 1.0e+00 WNT3
Medication for pain relief, constipation, heartburn 3.05 5 1 2.2 -0.97 7.4e-03 CEP170 GPX1 PCDH9 RP11-165J3.6 WNT3
Neck or shoulder pain in last month 3.20 2 0 0.0 0.00 1.0e+00 GPX1 RP5-1115A15.1
Mean time to correctly identify matches 3.15 2 2 4.4 -0.99 9.8e-03 ARHGAP1 LRP4
Whole body fat mass 3.12 10 5 11.1 -0.16 6.4e-01 ARNTL C1QTNF4 CEP170 DPY19L3 FTSJ2 GPX1 LINC00461 MADD RP11-159N11.4 RP5-1115A15.1
Leg fat mass (right) 3.16 10 5 11.1 -0.12 7.3e-01 ARNTL C1QTNF4 CEP170 DPY19L3 FTSJ2 GPX1 LINC00461 MADD RP11-159N11.4 RP5-1115A15.1
Arm predicted mass (right) 1.06 4 0 0.0 0.65 3.5e-01 GPX1 LINC00461 LRP4 NUP160
Pulse rate, automated reading 1.67 4 1 2.2 -0.99 7.1e-03 LINC00461 LMO4 ORC4L TOMM22
Alcohol intake frequency. 3.84 7 4 8.9 -0.09 8.3e-01 C1QTNF4 DCC DRD2 MADD RP11-159N11.4 TCF4 WNT3
Comparative height size at age 10 1.86 11 7 15.6 -0.30 3.7e-01 C1QTNF4 CMTR2 DLST GLB1L GPX1 LRP4 NUP160 RP5-1115A15.1 STAG1 TCF4 WNT3
Suffer from 'nerves' 8.27 8 4 8.9 0.95 3.6e-05 AATK ARHGAP1 C1QTNF4 DLST MADD NUP160 RP5-1115A15.1 WNT3
Overall health rating 4.38 7 3 6.7 0.99 3.9e-06 AATK CEP170 GPX1 NUDT18 PTK2 RP11-159N11.4 RP11-165J3.6
Age at last live birth 1.80 1 1 2.2 0.00 1.0e+00 GPX1
Leg pain on walking 2.09 1 0 0.0 0.00 1.0e+00 WNT3
Supplements: Vitamin C 1.41 1 0 0.0 0.00 1.0e+00 WNT3
Hypertension (Self-reported) 2.19 5 1 2.2 0.42 4.1e-01 ARHGAP1 ARNTL LRP4 MADD RP5-1115A15.1
Illnesses of father: Heart disease 1.34 2 0 0.0 0.00 1.0e+00 ICA1L WNT3
Forced expiratory volume in 1-second (FEV1), predicted 1.58 1 0 0.0 0.00 1.0e+00 C1QTNF4
Whole body fat-free mass 1.10 6 0 0.0 0.30 5.1e-01 ARHGAP1 GPX1 LINC00461 LRP4 NUP160 UBXN2A
Leg fat-free mass (right) 1.21 4 1 2.2 -0.38 6.2e-01 ARHGAP1 C1QTNF4 LINC00461 LRP4
Arm fat percentage (left) 4.77 9 8 17.8 -0.40 2.6e-01 ARNTL C1QTNF4 DPY19L3 FTSJ2 GPX1 LINC00461 MADD NUP160 RP5-1115A15.1
Handedness (chirality/laterality): Left-handed 1.84 1 1 2.2 0.00 1.0e+00 WNT3
Mood swings 11.70 24 12 26.7 0.99 9.5e-20 C1QTNF4 CD40 CELF4 CMTR2 DCC DLST DPY19L3 DRD2 GLB1L GPX1 LRP4 MADD NUP160 PLCL2 PRR16 PTK2 RP11-159N11.4 RP11-165J3.6 SLC12A5 STAG1 TCF4 TLR4 TMEM106B WNT3
Loneliness, isolation 9.37 11 5 11.1 0.98 6.0e-08 C1QTNF4 GPX1 MADD NUDT18 NUP160 ORC4L PCDH9 RP5-1115A15.1 STAG1 TMEM106B WNT3
Mouth/teeth dental problems: Mouth ulcers 1.90 1 1 2.2 0.00 1.0e+00 WNT3
Back pain experienced in last month 3.12 1 0 0.0 0.00 1.0e+00 PTK2
Asthma (self-reported) 1.42 1 1 2.2 0.00 1.0e+00 RP5-1115A15.1
Smoking status: Current 3.12 3 1 2.2 1.00 3.5e-03 AATK C1QTNF4 NUP160
Forced expiratory volume in 1-second (FEV1), predicted percentage 1.50 1 1 2.2 0.00 1.0e+00 WNT3
Whole body water mass 1.09 7 0 0.0 0.36 3.7e-01 ARHGAP1 DPY19L3 GPX1 LINC00461 LRP4 NUP160 UBXN2A
Leg predicted mass (right) 1.22 4 1 2.2 -0.38 6.2e-01 ARHGAP1 C1QTNF4 LINC00461 LRP4
Arm fat mass (left) 3.46 10 5 11.1 -0.25 4.6e-01 ARNTL C1QTNF4 CEP170 DPY19L3 FTSJ2 GPX1 LINC00461 MADD NUP160 RP5-1115A15.1
Number of self-reported non-cancer illnesses 3.39 4 1 2.2 0.58 4.2e-01 ARNTL FTSJ2 LRP4 TMEM106B
Average weekly champagne plus white wine intake 1.94 1 0 0.0 0.00 1.0e+00 WNT3
Miserableness 12.98 27 13 28.9 0.99 7.1e-24 ARHGAP1 ARNTL C1QTNF4 CD40 CELF4 DPY19L3 DRD2 FTSJ2 GPX1 ICA1L LINGO1 LMO4 LRP4 MADD MMAB NUP160 ORC4L PCDH9 RP11-159N11.4 RP11-165J3.6 RP5-1115A15.1 SLC12A5 STAG1 TCF4 TMEM106B UBXN2A WNT3
Guilty feelings 7.51 11 5 11.1 0.97 6.9e-07 AATK ARNTL C1QTNF4 CD40 DLST DRD2 LINGO1 MADD RP11-159N11.4 UBXN2A WNT3
Financial situation satisfaction 2.85 1 1 2.2 0.00 1.0e+00 GPX1
Medication: Paracetamol 2.99 3 1 2.2 0.00 1.0e+00 CEP170 GPX1 WNT3
Illnesses of father: High blood pressure 1.66 1 0 0.0 0.00 1.0e+00 MADD
Alcohol drinker status: Never 2.00 1 0 0.0 0.00 1.0e+00 C1QTNF4
Ever smoked 1.99 1 0 0.0 0.00 1.0e+00 AATK
Basal metabolic rate 1.11 5 1 2.2 0.49 4.0e-01 ARHGAP1 DPY19L3 GPX1 LINC00461 LRP4
Leg fat percentage (left) 3.87 10 6 13.3 -0.19 5.8e-01 ARNTL C1QTNF4 DPY19L3 GPX1 LINC00461 MADD NUDT18 NUP160 RP5-1115A15.1 UBXN2A
Arm fat-free mass (left) 1.08 4 1 2.2 1.00 3.7e-03 DPY19L3 GPX1 LINC00461 NUP160
Number of operations (self-reported) 2.30 2 0 0.0 0.00 1.0e+00 GPX1 RP5-1115A15.1
Average weekly beer plus cider intake 2.31 1 0 0.0 0.00 1.0e+00 CELF4
Irritability 6.49 12 4 8.9 0.98 2.3e-08 CELF4 CMTR2 DRD2 FTSJ2 GPX1 LINC00461 MMAB ORC4L TCF4 TLR4 TMEM106B WNT3
Fractured/broken bones in last 5 years 2.08 1 0 0.0 0.00 1.0e+00 WNT3
Diastolic blood pressure, automated reading 2.42 7 4 8.9 0.27 5.6e-01 ARNTL CEP170 GPX1 ICA1L LINC00461 MADD RP5-1115A15.1
Myopia 1.89 1 0 0.0 0.00 1.0e+00 FTSJ2
Vascular/heart problems diagnosed by doctor 2.31 5 1 2.2 -0.41 4.2e-01 ARHGAP1 ARNTL LRP4 MADD RP5-1115A15.1
Pain experienced in last month 3.85 4 1 2.2 -0.95 5.1e-02 GPX1 MMAB PTK2 WNT3
Heart attack/myocardial infarction (self-reported) 1.59 1 0 0.0 0.00 1.0e+00 ICA1L
Pack years of smoking 2.35 2 0 0.0 0.00 1.0e+00 CELF4 GPX1
Impedance of whole body 1.43 5 4 8.9 -0.70 1.9e-01 GPX1 LINC00461 STAG1 UBXN2A WNT3
Leg fat mass (left) 3.29 10 5 11.1 -0.20 5.6e-01 ARNTL C1QTNF4 CEP170 DPY19L3 FTSJ2 GPX1 LINC00461 MADD NUP160 RP5-1115A15.1
Arm predicted mass (left) 1.06 4 1 2.2 0.99 8.0e-03 DPY19L3 GPX1 LINC00461 NUP160

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 15 0.43 2.1
GTEx Adipose Visceral Omentum 12 0.59 2.3
GTEx Adrenal Gland 7 0.48 2.1
GTEx Artery Aorta 11 0.37 2.2
GTEx Artery Coronary 11 0.93 2.6
GTEx Artery Tibial 14 0.37 2.1
GTEx Brain Caudate basal ganglia 10 1.08 2.4
GTEx Brain Cerebellar Hemisphere 10 0.67 2.3
GTEx Brain Cerebellum 11 0.55 2.3
GTEx Brain Cortex 12 1.16 2.5
GTEx Brain Frontal Cortex BA9 7 0.76 2.5
GTEx Brain Hippocampus 6 1.15 2.6
GTEx Brain Hypothalamus 6 1.02 2.6
GTEx Brain Nucleus accumbens basal ganglia 7 0.81 2.4
GTEx Brain Putamen basal ganglia 5 0.80 2.5
GTEx Breast Mammary Tissue 11 0.56 2.3
GTEx Breast Mammary Tissue (Male) 7 0.59 2.2
GTEx Breast Mammary Tissue (Female) 11 0.67 2.3
GTEx Cells EBV-transformed lymphocytes 13 0.92 2.4
GTEx Cells Transformed fibroblasts 21 0.50 2.1
GTEx Colon Sigmoid 10 0.68 2.3
GTEx Colon Transverse 10 0.48 2.2
GTEx Esophagus Gastroesophageal Junction 14 0.97 2.5
GTEx Esophagus Mucosa 16 0.48 2.2
GTEx Esophagus Muscularis 19 0.59 2.2
GTEx Heart Atrial Appendage 10 0.63 2.2
GTEx Heart Left Ventricle 9 0.59 2.3
GTEx Liver 6 0.84 2.3
GTEx Lung 18 0.63 2.2
GTEx Muscle Skeletal 11 0.38 2.1
GTEx Nerve Tibial 13 0.30 2.0
GTEx Ovary 9 0.99 2.6
GTEx Pancreas 8 0.49 2.2
GTEx Pituitary 8 0.72 2.3
GTEx Prostate 9 1.08 2.5
GTEx Skin Not Sun Exposed Suprapubic 16 0.65 2.4
GTEx Skin Sun Exposed Lower leg 18 0.50 2.3
GTEx Small Intestine Terminal Ileum 5 1.08 2.7
GTEx Spleen 12 0.85 2.4
GTEx Stomach 9 0.62 2.3
GTEx Testis 15 0.48 2.2
GTEx Thyroid 16 0.40 2.1
GTEx Uterus 7 1.23 2.9
GTEx Vagina 5 0.79 2.5
GTEx Whole Blood 10 0.50 2.1
METSIM Adipose 12 0.26 1.9
NTR Blood 7 0.29 2.0
ROSMAP Brain Pre-frontal Cortex 13 0.30 2.0
YFS Blood 5 0.11 1.8
CommonMind Brain Pre-frontal Cortex 10 0.19 2.0
The Cancer Genome Atlas Bladder Urothelial Carcinoma 3 0.18 2.1
The Cancer Genome Atlas Breast Invasive Carcinoma 10 0.23 1.9
The Cancer Genome Atlas Cervical Squamous Cell Carcinoma 3 0.27 2.0
The Cancer Genome Atlas Colon Adenocarcinoma 4 0.19 2.1
The Cancer Genome Atlas Esophageal Carcinoma 4 0.59 2.4
The Cancer Genome Atlas Glioblastoma Multiforme 6 0.59 2.1
The Cancer Genome Atlas Head and Neck Squamous Cell Carcinoma 13 0.48 2.1
The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma 12 0.29 1.9
The Cancer Genome Atlas Kidney Renal Papillary Cell Carcinoma 6 0.29 2.0
The Cancer Genome Atlas Brain Lower Grade Glioma 13 0.30 1.9
The Cancer Genome Atlas Liver Hepatocellular Carcinoma 5 0.45 1.9
The Cancer Genome Atlas Lung Adenocarcinoma 9 0.31 2.0
The Cancer Genome Atlas Lung Squamous Cell Carcinoma 5 0.20 2.0
The Cancer Genome Atlas Ovarian Serous Cystadenocarcinoma 5 0.32 2.1
The Cancer Genome Atlas Pancreatic Adenocarcinoma 4 0.24 2.0
The Cancer Genome Atlas Pheochromocytoma and Paraganglioma 6 0.45 2.0
The Cancer Genome Atlas Prostate Adenocarcinoma 13 0.28 2.0
The Cancer Genome Atlas Rectum Adenocarcinoma 2 0.29 2.1
The Cancer Genome Atlas Soft Tissue Sarcoma 4 0.38 2.1
The Cancer Genome Atlas Skin Cutaneous Melanoma 1 0.19 1.7
The Cancer Genome Atlas Stomach Adenocarcinoma 6 0.36 2.1
The Cancer Genome Atlas Testicular Germ Cell Tumors 4 0.31 1.8
The Cancer Genome Atlas Thyroid Carcinoma 13 0.25 1.9
The Cancer Genome Atlas Uterine Corpus Endometrial Carcinoma 2 0.39 2.1